Radiotherapy Induced Oral Mucositis Treatment Market Proposal, Demand And Trade Analysis 2023 to 2033

 According to a new market research report published by Future Market insights, the global Radiotherapy Induced Oral Mucositis Treatment market is expected to grow at a CAGR of 5% from 2023 to 2033, reaching a market size of USD 4.89 Billion by 2033.



Radiotherapy-induced oral mucositis is a painful and debilitating side effect of radiotherapy treatment for cancer patients. It is estimated that approximately 40% to 100% of patients who undergo radiotherapy for head and neck cancer will develop Radiotherapy Induced Oral Mucositis. This condition can significantly impact patients' quality of life, causing pain, difficulty eating, and increased risk of infection. However, there are several treatments available for Radiotherapy Induced Oral Mucositis, including drugs, mouthwashes, gels, and other therapies.

Get a PDF Sample with the Latest Market Insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16820

The global Radiotherapy Induced Oral Mucositis Treatment Market is expected to grow significantly from 2018 to 2022, with a continued upward trajectory in demand from 2023 to 2033. One of the key drivers of the Radiotherapy Induced Oral Mucositis treatment market is the increasing incidence of cancer.

According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018. As the incidence of cancer continues to rise, the number of patients undergoing radiotherapy is also increasing, leading to a higher prevalence of Radiotherapy Induced Oral Mucositis.

Another factor driving the growth of the Radiotherapy Induced Oral Mucositis treatment market is the increasing awareness of Radiotherapy Induced Oral Mucositis among healthcare providers and patients. Radiotherapy Induced Oral Mucositis is a well-known side effect of radiotherapy, and healthcare providers are increasingly taking steps to prevent and manage this condition in their patients. Additionally, patients are becoming more informed about Radiotherapy Induced Oral Mucositis and are seeking out effective treatments to manage their symptoms.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/radiotherapy-induced-oral-mucositis-treatment-market

Key Takeaways from the Market Study

  • From 2018 to 2022, the Radiotherapy Induced Oral Mucositis Treatment market grew at a CAGR of 3.5%.
  • The global Radiotherapy Induced Oral Mucositis Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
  • As of 2033, the Radiotherapy Induced Oral Mucositis Treatment Market is expected to reach US$ 4.89 Billion.
  • According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
  • North America is expected to possess 40% market share for the Radiotherapy Induced Oral Mucositis Treatment market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Radiotherapy Induced Oral Mucositis Treatment.” says an FMI analyst

Mucositis Relief for Radiotherapy Patients is a common side effect of radiation therapy in cancer patients. It is an inflammation of the mucous membranes lining the mouth and throat, which can cause pain, discomfort, and difficulty swallowing.

Market Competition

  • Galera Therapeutics announced that the FDA has accepted and granted priority review to a new drug application for avasopasem manganese (GC4419) for patients suffering from radiotherapy-induced severe oral mucositis caused by head and neck cancer. The Prescription Drug User Fee Act date for avasopasem has been set for August 9, 2023. If approved, avasopasem will be the first drug approved by the FDA for reducing radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

Key Companies Profiled:

  • Izun Pharmaceuticals
  • Soleva Pharma
  • Aurora Bioscience
  • INNOVATION Pharma
  • Camurus AB, Monopar Therapeutics
  • Prothex Inc.
  • Access Pharmaceutical Inc.
  • Swedish Orphan Biovitrum
  • NeoMedLight

Key Segments Profiled in the Radiotherapy-Induced Oral Mucositis Treatment Industry Survey

Drug Class:

  • Antibiotics
  • Antifungal
  • Anti-Inflammatory
  • Anti-Neoplastic

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End User:

  • Hospitals
  • Oncology Centres
  • Research Institutes
  • Dental Clinics

Comments

Post a Comment

Popular posts from this blog

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer re...
Read more